Candidemia

05/04/2021 - "Collectively, our data will complete the candidemia picture in Iran and show that, although the level of resistance was rare, the therapeutic failure was notable among NAC species, which threatens the efficacy of fluconazole, the most widely used antifungal in Southern regions of Iran. "
03/01/2021 - "However, the high susceptibility of Candida spp. isolates to fluconazole may invite to reconsider the use of this molecule as empirical and first-line treatment of candidemia in Mayotte."
01/01/2000 - "Fluconazole was administered as the first line agent in 6 episodes and successfully cleared candidemia in 5 episodes. "
01/01/2018 - "Furthermore, isolates recovered from immunocompetent patients with persistent candidemia display higher tolerance than isolates readily cleared by fluconazole. "
12/06/2022 - "Previous Brazilian studies have reported the presence of endemic Candida parapsilosis sensu stricto genotypes causing candidemia and clonal transmission involving fluconazole-resistant isolates. "

12/01/2010 - "Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."
11/01/2005 - "In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. "
05/15/2013 - "Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different. "
02/01/2022 - "Larger studies are needed to confirm whether standard doses of anidulafungin are sufficient for candidemia in obese patients."
05/15/2013 - "An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. "

12/01/2023 - "Echinocandins are recommended as first-line treatment of candidemia. "
08/01/2022 - "This study aims to further explore the duration of echinocandins and analyze the de-escalation (DE) strategy in patients with candidemia. "
05/21/2021 - "Our study shows the importance of sequencing to predict therapeutic failure in patients treated with echinocandins and persistent candidemia."
08/01/2018 - "albicans as the first cause of candidemia in all the studied settings and the low rate of echinocandin resistance, despite their increased use over the study period. "
11/01/2015 - "Of 1,395 Candida bloodstream isolates, 79 from 68 patients were uncommon Candida spp. The incidence density of uncommon Candida spp. BSIs and their proportion to all candidemia episodes substantively increased during the study period, and the rise was associated with increasing use of echinocandin antifungal drugs. "

03/01/2004 - "The addition of caspofungin resulted in rapid clearance of the candidemia. "
01/01/2014 - "Secondary antifungal prophylaxis with caspofungin was found effective in treating six FN episodes in three patients who had experienced at least two persistent candidemia attacks. "
03/01/2014 - "Caspofungin successfully treated persistent candidemia in extremely premature infants at 23 and 24 weeks' gestational age."
03/01/2014 - "There was no recurrent candidemia after discontinuing caspofungin. "
03/01/2014 - "Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks' gestation."

02/01/2009 - "In this study, the susceptibility to amphotericin B of Candida spp. isolates obtained from patients with candidemia was related to their respective clinical outcomes. "
05/01/1997 - "A protocol amendment implemented midway through the trial required patients to be removed from the study and treated with amphotericin B if species identification indicated candidemia due to Candida glabrata or Candida krusei. "
12/30/2021 - "Amphotericin B has been recommended as the primary treatment; however, its use is limited due to drug-induced nephrotoxicity and amphotericin B-resistant candidemia. "
12/21/2020 - " Candida lusitaniae is a rare cause of candidemia that is known for its unique capability to rapidly acquire resistance to amphotericin B. "
03/01/2014 - "Amphotericin B has been recommended as the primary treatment; however, its use is limited due to drug-induced nephrotoxicity and amphotericin B-resistant candidemia. "

11/01/2003 - "Micafungin is effective against candidemia due to C. "
10/01/2005 - "Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. "
04/01/2005 - "It is suggested that micafungin is useful for the treatment of candidemia associated with Candida parapsilosis."
03/06/2022 - "auris was cleared from the urine, the patient subsequently developed breakthrough candidemia and the bloodstream isolate exhibited a reduced susceptibility to micafungin and also showed the presence of a novel (S639T) mutation in hotspot-1 of FKS1. "
10/01/2005 - "Efficacy of micafungin for the treatment of candidemia."

05/01/2001 - "Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. "
09/01/2015 - "Improved treatment of candidemia may ultimately be achieved by optimizing the use of antifungal agents rather than the development of new drugs."
10/01/2003 - "Given the continuing progress in clinical research infrastructure and development of new diagnostic tests and antifungal agents, substantial improvement in the prevention, diagnosis, and management of neonatal candidemia is plausible over the next decade."
11/01/2021 - "The study subjects included adult patients ≥ 19 years with candidemia treated with antifungal agent for ≥ 3 days. "
04/01/2014 - "The purpose of this study is to investigate the risk factors and susceptibilities to antifungal agents of Candida albicans and Candida non-albicans species (spp.) in candidemia cases in Kobe University Hospital. "

01/01/2022 - "auris isolates increased significantly during the study period as did the overall proportion of azole-resistant candidemia. "
11/01/2020 - "In this study, we conducted a meta-analysis of randomized controlled trials regarding the efficacy and safety of azole and polyene antifungals in the treatment of candidemia. "
01/01/2016 - "Candida glabrata is the second most common cause of candidemia worldwide and presents higher levels of intrinsic azole resistance when compared with Candida albicans, thus being an interesting subject for the study of azole resistance mechanisms in fungal pathogens.Since"
01/01/2023 - "glabrata had significantly lower azole susceptibility than non-candidemia-causing isolates. "
01/01/2022 - "The proportion of azole-resistant candidemia cases increased from 21/53 (39.6%) in 2016 to 41/59 (69.5%) in 2020 (p = 0.002). "

06/01/2004 - "Pfizer's Vfend as effective in treating candidemia as two-drug standard of care according to study."
05/01/2008 - "The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia. "
01/01/2022 - "This review focuses on our AFS efforts to standardize treatment using a template for pharmacist-led patient intervention for candidemia and to evaluate TDM dosage adequacy rates for voriconazole. "
05/01/2008 - "Results of the decision-analytical model provided evidence to support the cost-effectiveness of voriconazole relative to a regimen of CAB/FLU in the treatment of non-neutropenic patients diagnosed with candidemia in the Canadian setting."
05/01/2008 - "Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults."

11/29/2017 - "This education-based antimicrobial stewardship program was effective in decreasing the incidence and mortality rate of hospital-acquired candidemia and MDR BSI through sustained reduction in antibiotic use."
04/25/2023 - "This study concluded that many antibiotics were safe for candidemia patients. "
10/01/2011 - "In this study, the effectiveness of the commercially available antifungal drugs, which are commonly used in candidemia, were assessed in an in vitro antibiotic lock model. "
10/01/1989 - "It remains to be shown in controlled clinical trials whether limiting the number of antibiotics or instituting prophylaxis and/or early treatment for high-risk patients will reduce the incidence of nosocomial candidemia."
11/23/2023 - "auris candidemia included antibiotic use (91.3 %), especially for > 14 days (78.3 %), C. "

10/01/2019 - "Antimicrobial stewardship program review of automated alerts identifying patients with candidemia resulted in significantly improved BOC adherence and was associated with a 1.5-hour reduction in time to initiation of antifungal therapy. "
06/01/2002 - "As many patients with candidemia will have died by the time laboratory diagnosis is made, presumptive antifungal therapy in high-risk patients may be necessary if outcome is to be improved."
04/01/2002 - "albicans candidemia had a significantly greater overall response to therapy (83/104 [80%] vs. 60/97 [62%], P = 0.005) and to primary therapy (74/104 [71%] vs. 45/97 [46%], P = 0.0003). "
01/01/2018 - "Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial."
10/27/2023 - "Evidence-driven candidemia treatment durations are imperative to balance efficacy with resistance prevention and ensure the longevity of antifungal therapies. "

10/01/2011 - "Positive blood culture is the gold standard of candidemia; it should not be accepted as contamination or colonization in children with an intravascular catheter. "
08/01/2009 - "LE-inducible candidal virulence determinants, such as germination and enhanced biofilm production, may help to explain the increased risk of candidemia in patients receiving LE via medical catheters."
09/01/2020 - "In our study, the most important source of candidemia was catheter, and C. "
06/01/2018 - "Regarding this, the aim of the current study was to identify the prevalence of catheter-induced candidemia in the Tehran Heart Center, a heart hospital in Tehran, Iran. "
03/01/2017 - "In this study, when the origin of candidemia was not the CVC, patients were more seriously ill, had a higher mortality rate, and the removal of the catheter seemed to lead to disappointing results. "

10/27/2023 - "Further research and clinical trials are needed to establish evidence-based guidelines for candidemia treatment duration."
01/01/2021 - "Additional studies are needed to determine the optimal duration of therapy following candidemia clearance."
10/27/2023 - "Questioning the 14-day dogma in candidemia treatment duration."
01/01/2021 - "Our data support the IDSA guidelines in that the total duration of treatment for candidemia should be at least 14 days after a negative blood culture. "
01/01/2018 - "In conclusion, the T2MR assay significantly outperformed blood cultures for monitoring the clearance of candidemia in patients receiving antifungal therapy and may be useful in determining adequate source control, timing for deescalation, and optimal duration of treatment. "

12/01/1999 - "Data on an improved outcome of candidemia if a central venous catheter is removed promptly are conflicting. "
11/01/2018 - "The impact of central venous catheter (CVC) removal on the outcome of patients with candidemia is controversial, with studies reporting discrepant results depending on the time of CVC removal (early or any time during the course of candidemia). "
08/01/2010 - "Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials."
01/01/2022 - "Presence of central venous catheter and diabetes were statistically significant risk factors for development of candidemia by NAC. "
05/01/2021 - "The morbidity and mortality of candidemia originating from a central venous catheter (CVC) and illicit intravenous drug use (IVDU) are increasing. "

11/01/2005 - "The impact of candidemia on excess mortality, increased length of stay, and the burden of cost of hospitalization underscores the need for improved means of prevention and treatment of candidemia in adults and children."
02/01/2023 - "The primary outcome of the study was mortality, and the secondary outcomes were the development of candidemia and length of hospital stay. "
02/01/2023 - "This study aimed to evaluate the effects of different AF treatment approaches (prophylactic, empirical, and culture-directed) on mortality, development of candidemia, and length of hospital stay in these patients. "
12/01/2023 - "Hospital stays were prolonged due to need of iv AF Tx in 16% of patients with candidemia. "
12/01/2023 - "Hospital stay was prolonged solely for the completion of iv AF Tx in 16% (100/621) of candidemia cases by a median of 16 days (IQR 8 - 28). "